Article Information
History
- March 12, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Michael Dougan, MD, PhD1,
- Masoud Azizad, MD2,
- Peter Chen, MD3,
- Barry Feldman, MD4,
- Matthew Frieman, PhD5,
- Awawu Igbinadolor, MD6,
- Princy Kumar, MD7,
- Jason Morris, MD8,
- Jeffrey Potts, MD9,
- Lauren Baracco, BS5,
- Lisa Macpherson, MSPHc10,
- Nicole L. Kallewaard, PhD10,
- Dipak R. Patel, MD, PhD10,
- Matthew M. Hufford, PhD10,
- Linda Wietecha, MSc10,
- Emmanuel Chigutsa, PhD10,
- Sarah L. Demmon, MS10,
- Bryan E. Jones, PhD10,
- Ajay Nirula, MD, PhD10,
- Daniel M. Skovronsky, MD, PhD10,
- Mark Williams, MD, FCCM, FCCP10 and
- Robert L. Gottlieb, MD, PhD11,*
- 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 2Valley Clinical Trials, Northridge, CA, USA
- 3Cedars–Sinai Medical Center, Los Angeles, CA, USA
- 4Millennium Medical Group, Farmington Hills, MI, USA
- 5University of Maryland School of Medicine, Baltimore, MD
- 6Monroe Biomedical Research, Monroe, NC, USA
- 7Georgetown University, Washington, DC, USA
- 8Clinical Trials of Southwest Louisiana, Lake Charles, LA, USA
- 9Great Lakes Research Group, Inc., Bay City, MI, USA
- 10Eli Lilly and Company, Indianapolis, IN, USA
- 11Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX, USA
- ↵*Corresponding author:
Robert L. Gottlieb, MD, PhD, Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX, USA. E-mail: Robert.Gottlieb{at}BSWHealth.org. Phone: +1-214-820-6856 (Office).
Posted March 12, 2022.
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
